Related Experiment Videos
Responsiveness of subcutaneous human glioma xenografts to various antitumor agents
Abstract:
Responsiveness of seven human glioma xenografts to seven antitumor agents was investigated by an sc-iv system and the efficacies of these agents against human glioma were evaluated in terms of response rate. When their maximum tolerated doses were used, experimental response rates of nimustine (ACNU), vincristine (VCR), adriamycin (ADR) and vinblastine (VLB) were as high as 86-100%, while that of mitomycin (MMC) was 57%, and those of 5-fluorouracil (5-FU) and methotrexate (MTX) were 0%. On the other hand, when the doses pharmacokinetically equivalent to their clinical doses were employed, the response rate of ADR was the highest, followed by VCR and ACNU in this order. These results suggest that gliomas are significantly responsive to various antitumor agents in this sc-iv system.
Insights
Human gliomas show significant responsiveness to several antitumor agents, including nimustine (ACNU), vincristine (VCR), and adriamycin (ADR), when tested using an sc-iv system at maximum tolerated doses.
Area of Science:
- Oncology
- Pharmacology
Background:
- Human gliomas are aggressive brain tumors with limited treatment options.
- Evaluating the efficacy of various chemotherapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the responsiveness of human glioma xenografts to seven different antitumor agents.
- To compare the efficacies of these agents using an sc-iv system at maximum tolerated doses and clinically equivalent doses.
Main Methods:
- Utilized an sc-iv (subcutaneous-intravenous) system to test seven human glioma xenografts against seven antitumor agents.
- Evaluated drug efficacy based on response rates at maximum tolerated doses and pharmacokinetically equivalent doses.
Main Results:
- At maximum tolerated doses, nimustine (ACNU), vincristine (VCR), adriamycin (ADR), and vinblastine (VLB) showed high response rates (86-100%).
- Mitomycin (MMC) had a 57% response rate, while 5-fluorouracil (5-FU) and methotrexate (MTX) showed 0% response.
- At clinically equivalent doses, adriamycin (ADR) demonstrated the highest response rate, followed by VCR and ACNU.
Conclusions:
- Human gliomas exhibit significant responsiveness to a range of antitumor agents in the sc-iv model.
- The sc-iv system provides a valuable platform for preclinical evaluation of glioma treatment strategies.